<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112626">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01905566</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2012-02</org_study_id>
    <nct_id>NCT01905566</nct_id>
  </id_info>
  <brief_title>Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation</brief_title>
  <official_title>Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation: Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To compare the effects of clopidogrel versus ticagrelor on atherosclerotic
      plaque inflammation using serial FDG PET/CT imaging of carotid artery and ascending aorta.

      Hypothesis: Thrombosis and inflammation are tightly linked rather than separate entities.
      Therefore, P2Y12 receptor inhibitors may have an anti-ischemic effect by inhibiting plaque
      inflammation, and ticagrelor may be superior in efficacy to clopidogrel.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>change (follow-up minus baseline) in standardized FDG uptake value within the regions of interest</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analyses of FDG activity will be quantified on common carotid arteries and ascending aorta of the aortic arch. Primary endpoint is change (follow-up minus baseline) in standardized FDG uptake value within the regions of interest, known as a target-to-background ratio(blood-normalized standardized uptake value).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serial changes of high-sensitivity C-reactive protein</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial changes of lipid battery</measure>
    <time_frame>6months</time_frame>
    <safety_issue>No</safety_issue>
    <description>lipid battery (total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Plaque, Atherosclerotic</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clopidogrel: 75mg once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ticagrelor: 90mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75mg once a day</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>90mg twice a day</description>
    <arm_group_label>Ticagrelor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or Women at least 18 years of age inclusive

          -  Patients with acute coronary syndromes (unstable angina pectoris Braunwald class IB,
             IC, IIB, IIC, IIIB, IIIC, NSTEMI or STEMI)

          -  FDG PET/CT shows at least 1 hot uptakes at carotid and or ascending aorta

          -  The patient or guardian agrees to the study protocol and the schedule of clinical and
             FDG PET/CT follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          -  Patients treated with carotid endarterectomy or stent placement

          -  Chronic disease requiring treatment with oral, intravenous, or intra-articular
             corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).

          -  Untreated hyperthyroidism, or hypothyroidism

          -  Any clinically significant abnormality identified at the screening visit, physical
             examination, laboratory tests, or electrocardiogram which, in the judgment of the
             Investigator, would preclude safe completion of the study.

          -  Evidence of congestive heart failure, or left ventricular ejection fraction &lt; 40%.

          -  Significant renal disease manifested by serum creatinine &gt; 2.0mg/dL, or creatinine
             clearance of &lt; 40 ml/min (by Cockcroft-Gault method).

          -  Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation
             (ALT or AST &gt; 3 times upper limit of normal).

          -  History of adult asthma manifested by bronchospasm in the past 6 months, or currently
             taking regular anti-asthmatic medication(s).

          -  Unwillingness or inability to comply with the procedures described in this protocol.

          -  Patient's pregnant or breast-feeding or child-bearing potential.

          -  Type I Diabetes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheol-whan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheol-whan Lee, MD, PhD</last_name>
    <phone>82-2-3010-3158</phone>
    <email>cheolwlee@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong-youn Bae</last_name>
    <phone>82-2-3010-7259</phone>
    <email>cvcrc10@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheol-whan Lee, MD, PhD</last_name>
      <phone>82-2-3010-6158</phone>
      <email>cheolwlee@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Jeong-youn Bae</last_name>
      <phone>82-2-3010-7259</phone>
      <email>cvcrc10@amc.seoul.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Cheol-whan Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 27, 2013</lastchanged_date>
  <firstreceived_date>July 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Plaque, Atherosclerotic</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>Fluorodeoxyglucose F18</keyword>
  <keyword>Positron-Emission Tomography and Computed Tomography</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
